biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Prothena option

<< Previous

Bullboard Posts

Next >>

Post by barsaxon Jan 31, 2021 11:25am

232 Views

Post# 32431300

Prothena option

Before anybody gets their hopes up about the Prothena option extension, you must read note 13 from the interim finacial statements (near the bottom of page 19):

"The option target, milestone and royalty payments represent variable consideration. The Company determined that at this point in time it is remote that any of these payments will be made due to the current state of development of the technology. Therefore, the Company did not record any of the variable consideration as revenue."

That doesn't sound promising to me, so caution on the Prothena deal is warranted (IMHO)

<< Previous

Bullboard Posts

Next >>

AI companies to invest in